Related Experiment Video
Updated: Jul 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[New treatment options in chronic hepatitis B]
1Centro di Epatologia, Dipartimento di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo e Università degli Studi di Pavia, Italy.
Four antiviral drugs, including lamivudine, adefovir dipivoxil, entecavir, and telbivudine, are used for chronic hepatitis B (CHB). Telbivudine shows promising efficacy, tolerability, and a good genetic barrier for CHB treatment.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Context:
- Chronic hepatitis B (CHB) management involves nucleoside/nucleotide analogues.
- Four agents are currently available: lamivudine, adefovir dipivoxil, entecavir, and telbivudine.
- Telbivudine, a deoxythymidine analogue, is newly available in Italy.
Purpose:
- To review and compare the efficacy and resistance profiles of available antiviral therapies for CHB.
- To highlight the characteristics of telbivudine as a potential first-line treatment option.
Summary:
- Lamivudine offers good bioavailability and viral load reduction but has a low genetic barrier.
- Adefovir dipivoxil has a better genetic barrier than lamivudine but sub-optimal efficacy at approved doses; it is effective against lamivudine-resistant strains.
- Entecavir demonstrates significant viral replication inhibition and a high genetic barrier in both naive and lamivudine-resistant patients.
- Telbivudine exhibits rapid virologic response, a good genetic barrier, excellent tolerability, and specific activity against HBV, positioning it as a preferred choice.
Impact:
- Provides a comparative overview of CHB antiviral treatments.
- Identifies telbivudine as a promising first-line therapy due to its favorable efficacy, safety, and resistance profile.
- Informs clinical decision-making for CHB management.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inhibitors of Viral Protein Synthesis
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
